422 related articles for article (PubMed ID: 37990309)
21. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
[TBL] [Abstract][Full Text] [Related]
22. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
23. Exploring the mechanism of 6-Methoxydihydrosanguinarine in the treatment of lung adenocarcinoma based on network pharmacology, molecular docking and experimental investigation.
Liu X; Ren Y; Qin S; Yang Z
BMC Complement Med Ther; 2024 May; 24(1):202. PubMed ID: 38783288
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the mechanism of Prunella vulgaris in treatment of papillary thyroid carcinoma based on network pharmacology integrated molecular docking and experimental verification.
Zhu X; Li Y; Wang X; Huang Y; Mao J
Medicine (Baltimore); 2023 Apr; 102(17):e33360. PubMed ID: 37115092
[TBL] [Abstract][Full Text] [Related]
25. Network pharmacology and experimental verification of the potential mechanism of Er-Xian decoction in aplastic anemia.
Ye M; Liu G; Yang Y; Yang H; Ren J; Chen W; Gao Z
Sci Rep; 2023 Oct; 13(1):17385. PubMed ID: 37833363
[TBL] [Abstract][Full Text] [Related]
26. Mechanism exploration and prognosis study of Astragali Radix-Spreading hedyotis herb for the treatment of lung adenocarcinoma based on bioinformatics approaches and molecular dynamics simulation.
Guo J; Zhao Y; Wu X; Li G; Zhang Y; Song Y; Du Q
Front Chem; 2023; 11():1128671. PubMed ID: 37065830
[No Abstract] [Full Text] [Related]
27. The potential mechanism of Bletilla striata in the treatment of ulcerative colitis determined through network pharmacology, molecular docking, and in vivo experimental verification.
Gong S; Lv R; Fan Y; Shi Y; Zhang M
Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):983-1000. PubMed ID: 36576506
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
29. Study the Mechanism of Gualou Niubang Decoction in Treating Plasma Cell Mastitis Based on Network Pharmacology and Molecular Docking.
Wu Z; Yang Q; Ma H
Biomed Res Int; 2022; 2022():5780936. PubMed ID: 35757473
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
Yu T; Xia Q; Gong T; Wang J; Zhong D
Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.
Xu Z; Hao X; Lin L; Li J; Xing P
Thorac Cancer; 2021 Aug; 12(16):2233-2240. PubMed ID: 34180588
[TBL] [Abstract][Full Text] [Related]
32. Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway.
Yang CZ; Guo W; Wang YF; Hu LH; Wang J; Luo JM; Yao XH; Liu S; Tao LT; Sun LL; Lin LZ
J Ethnopharmacol; 2023 Oct; 314():116566. PubMed ID: 37169317
[TBL] [Abstract][Full Text] [Related]
33. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
34. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
35. [Effect of "Hedyotis Diffusae Herba-Smilacis Glabrae Rhizoma" in treatment of lung adenocarcinoma based on network pharmacology].
Li JL; Hou W
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(23):6261-6270. PubMed ID: 34951253
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of resistance mechanisms to EGFR-TKIs and establishment and validation of prognostic model.
Yang Z; Li H; Dong T; Li G; Chen D; Li S; Wang Y; Pan Y; Lu T; Yang G; Zhang G; Cheng P; Wang X
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13773-13792. PubMed ID: 37532906
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism of vitiligo treatment by bailing tablet based on network pharmacology and molecular docking.
Li J; Yang M; Song Y
Medicine (Baltimore); 2022 Jul; 101(26):e29661. PubMed ID: 35777015
[TBL] [Abstract][Full Text] [Related]
38. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X; Maity TK; Ross KE; Qi Y; Cultraro CM; Bahta M; Pitts S; Keswani M; Gao S; Nguyen KDP; Cowart J; Kirkali F; Wu C; Guha U
Cancer Res; 2021 Jun; 81(11):3051-3066. PubMed ID: 33727228
[TBL] [Abstract][Full Text] [Related]
39. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
